mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors.
| Τίτλος | mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors. |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Koletsa, T., Petrakis G., Karayannopoulou G., Euvrard S., & Kanitakis J. |
| Journal | Anticancer Res |
| Volume | 38 |
| Issue | 6 |
| Pagination | 3319-3322 |
| Date Published | 2018 Jun |
| ISSN | 1791-7530 |
| Λέξεις κλειδιά | Carcinoma, Squamous Cell, Humans, Immunohistochemistry, Immunosuppressive Agents, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction, Sirolimus, Skin Neoplasms, Time Factors, TOR Serine-Threonine Kinases, Transplantation |
| Abstract | BACKGROUND/AIM: Inhibitors of the mammalian target of rapamycin (mTORis) exert immunosuppressive and antitumor effects and are used in organ-transplant recipients (OTR) as immunosuppressants able to reduce skin tumor burden. This study investigated the effects of mTORis on the expression of mTOR pathway proteins in cutaneous squamous-cell carcinomas (SCC) developing in OTR, before and after switching to mTORis.MATERIALS AND METHODS: An immunohistochemical study was performed on 23 SCC sections excised from OTR with post-transplant SCC, before or after switch to mTORis, with antibodies against pAkt, pmTOR and PI3K.RESULTS: pmTOR expression was found in 8/12 SCC pre-switch, and in 8/11 SCC post-switch, to mTORis. All (but 2) SCC expressed PI3K, and all SCCs expressed pAkt.CONCLUSION: mTORis do not significantly change the immunohistochemical expression of molecules upstream of the mTOR inhibition (pmTOR, PI3K, pAkt), in cutaneous SCC. |
| DOI | 10.21873/anticanres.12597 |
| Alternate Journal | Anticancer Res. |
| PubMed ID | 29848679 |
